| Bausch Health Announces 2025 Annual Meeting of Shareholder Results |
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Thomas J. |
accessnewswire.com |
2025-05-14 20:15:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for May 13th |
ALTI, AMRK and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2025. |
zacks.com |
2025-05-13 11:30:35 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today's announcement reinforces Bausch + Lomb's commitment to equip cataract surgeons with choices to fit the right lens to the right patient f. |
businesswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization |
New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced new data showing that people hospitalized due to overt hepatic encephalopathy (OHE) had a reduced risk of OHE-related rehospitalization within 30 days if treated with Xifaxan® (rifaximin) following hospital discharge regardless of prior treatment. These findings, based on a claims-based analysis, will be presented today at Digestive Disease Week® (DDW) 2025 in San Diego, CA. |
accessnewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down |
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. |
zacks.com |
2025-05-01 14:50:46 |
Czytaj oryginał (ang.) |
| Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-01 01:31:04 |
Czytaj oryginał (ang.) |
| Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates |
Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.59 per share a year ago. |
zacks.com |
2025-05-01 01:05:29 |
Czytaj oryginał (ang.) |
| Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript |
Bausch Health Companies Inc. (NYSE:BHC ) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Nedelcovych - TD Cowen Jason Gerberry - Bank of America Michael Freeman - Raymond James Operator Greetings. Welcome to the Bausch Health First Quarter 2025 Earnings Call. |
seekingalpha.com |
2025-04-30 23:51:44 |
Czytaj oryginał (ang.) |
| Bausch Health Announces First Quarter 2025 Results |
First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies of $58 million and GAAP Net Loss of $86 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP) 1 of $661 million, in line with prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2025 RESULTS Eighth consecutive quarter of year-over-year Revenue and Adjusted EBITDA (non-GAAP) 1 growth, with 6% and 14% growth versus the prior year period, respectively With strong financial momentum, remain committed to evaluating all options to unlock shareholder value, including maximizing the value of assets and share buybacks Successfully completed $7.9B refinancing in early April to extend near- and medium- term maturities Received favorable ruling from D.C. District Court in Norwich's case against the FDA Maintaining full-year 2025 Revenue and Adjusted EBITDA (non-GAAP) 1 guidance, with Adjusted Cash Flow from Operations (non-GAAP) 1 guidance updated primarily to reflect higher interest expense LAVAL, QC / ACCESS Newswire / April 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2025 financial results and other key updates from the quarter. |
accessnewswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System |
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX, the latest generation of the globally-recognized Thermage® system for non-invasive skin tightening and contouring. "The clearance of Thermage FLX in Canada is a positive development for our company and important for the continued growth of our aesthetic business", said Thomas J. |
accessnewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report? |
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-04-24 17:15:54 |
Czytaj oryginał (ang.) |
| Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth |
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-23 15:07:48 |
Czytaj oryginał (ang.) |
| Bausch Health Learns Icahn Has 34% Economic Interest in Shares |
Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health. |
wsj.com |
2025-04-22 13:33:00 |
Czytaj oryginał (ang.) |
| Bausch Health says Carl Icahn has exposure to about 34% of company's shares |
Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday. |
reuters.com |
2025-04-22 12:54:23 |
Czytaj oryginał (ang.) |
| Bausch Health Announces Filing of Supplement to Proxy Statement |
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX: BHC) (the "Company" or "Bausch Health") today announced that it has filed a supplement (the "Proxy Statement Supplement") to its proxy statement dated April 2, 2025 (the "Proxy Statement") in respect of the Company's upcoming annual general meeting of shareholders on May 13, 2025. The Company is updating the Proxy Statement to disclose, in addition to the 34,721,118 common shares reported as being beneficially owned (9.4%), Mr. |
accessnewswire.com |
2025-04-22 11:25:00 |
Czytaj oryginał (ang.) |
| Bausch (BHC) Moves 13.3% Higher: Will This Strength Last? |
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-21 15:25:36 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 103,169,500 units, or 625,026 pounds, of used contact lenses, eye care and lens care materials in the United States. That's equivalent to the weight of approximately 600 concert grand pianos1. “These award-winnin. |
businesswire.com |
2025-04-21 11:00:00 |
Czytaj oryginał (ang.) |
| U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich |
LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Kennedy, et al. |
accessnewswire.com |
2025-04-17 19:40:00 |
Czytaj oryginał (ang.) |
| Bausch Health Announces Adoption of Shareholder Rights Plan |
LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approved the adoption of a shareholder rights plan (the "SRP") pursuant to a shareholder rights plan agreement entered into with TSX Trust Company, as rights agent, dated April 14, 2025 (the "Effective Date"). The SRP has been adopted to help ensure that all shareholders of the Company are treated fairly and equally in connection with any unsolicited take-over bid or other acquisition of control of the Company (including by way of a "creeping" take-over bid) and that the Board has the opportunity to identify, solicit, develop and negotiate value-enhancing alternatives to any unsolicited take-over bid or similar transaction. |
accessnewswire.com |
2025-04-14 20:30:00 |
Czytaj oryginał (ang.) |
| Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program |
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)and its dermatology business, Ortho Dermatologics, today announced the 2025 ASPIRE HIGHER Scholarship Program is now open for application submissions through June 11, 2025. The program will award six exceptional students, impacted by dermatologic conditions, a scholarship of up to $10,000 in support of their higher education goals. |
accessnewswire.com |
2025-04-10 20:15:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room |
Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment. |
seekingalpha.com |
2025-02-21 15:33:06 |
Czytaj oryginał (ang.) |
| Bausch Health Q4 Earnings Recap (Reiterating Buy Rating) |
Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally. Key growth drivers include Salix, Xifaxan, and Solta, with a focus on long-term growth and debt management, peaking in 2028. Positive catalysts include FDA litigation outcomes and strategic decisions around Bausch & Lomb, enhancing shareholder value and future revenue potential. |
seekingalpha.com |
2025-02-20 20:01:12 |
Czytaj oryginał (ang.) |
| Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales |
BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive. |
zacks.com |
2025-02-20 16:30:38 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-19 23:00:23 |
Czytaj oryginał (ang.) |
| Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript |
Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Freeman - Raymond James Michael Nedelcovych - TD Cowen Glen Santangelo - Jefferies Operator Greetings. Welcome to the Bausch Health Fourth Quarter 2024 Earnings Call. |
seekingalpha.com |
2025-02-19 22:28:08 |
Czytaj oryginał (ang.) |
| Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates |
Bausch Health (BHC) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.15 per share a year ago. |
zacks.com |
2025-02-19 22:26:07 |
Czytaj oryginał (ang.) |
| Bausch Health Announces Fourth Quarter and Full-Year 2024 Results |
Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year period Full-Year Consolidated Revenues of $9.63 billion, up 10% on a Reported basis and 8% on an Organic (non-GAAP)1 basis, with growth in all segments GAAP Net Income Attributable to Bausch Health Companies Inc. of $93 million for the quarter and GAAP Net Loss of $46 million for the year Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $935 million for the quarter, up 8%, and $3.31 billion for the year, up 10% LAVAL, QC / ACCESS Newswire / February 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth quarter and full-year 2024 financial results and other key updates for the quarter. "2024 was a year of delivering on our commitments, where we achieved the high-end of our revenue guidance range, and exceeded our adjusted EBITDA excluding Bausch + Lomb, and adjusted operating cash flow guidance expectations. |
accessnewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 financial results. “Underpinning our recent success is a commitment to long-term, profitable growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for pati. |
businesswire.com |
2025-02-19 08:58:00 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Bausch (BHC) Q4 Earnings |
Beyond analysts' top -and-bottom-line estimates for Bausch (BHC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-17 12:20:56 |
Czytaj oryginał (ang.) |
| Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference |
LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24. |
accessnewswire.com |
2025-02-14 10:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline |
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-12 13:06:55 |
Czytaj oryginał (ang.) |
| Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More |
Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth |
globenewswire.com |
2025-02-12 07:41:00 |
Czytaj oryginał (ang.) |
| Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program |
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals. |
accessnewswire.com |
2025-02-10 10:00:00 |
Czytaj oryginał (ang.) |
| Contact lens maker Bausch + Lomb rules out take-private deal |
Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday. |
reuters.com |
2025-02-06 09:27:59 |
Czytaj oryginał (ang.) |
| Bausch Health Provides Update on Strategic Alternatives |
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation. |
accessnewswire.com |
2025-02-06 09:05:00 |
Czytaj oryginał (ang.) |
| Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025 |
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. |
accessnewswire.com |
2025-01-23 09:00:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website p. |
businesswire.com |
2025-01-22 09:00:00 |
Czytaj oryginał (ang.) |
| Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program |
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program. We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) who gave XIFAXAN® the highest possible recommendation (Grade I, A,1) via their practice guidelines. |
accessnewswire.com |
2025-01-17 11:25:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High? |
The mean of analysts' price targets for Bausch (BHC) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-16 13:01:29 |
Czytaj oryginał (ang.) |
| Bausch + Lomb CEO on the negative impact of screen time on eye health |
Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision. |
youtube.com |
2025-01-14 16:15:00 |
Czytaj oryginał (ang.) |